Johnson & Johnson’s single-dose Covid-19 vaccine protects against the coronavirus, the U.S. Food and Drug Administration said on Wednesday, as it gears up to make a final decision on approval later in the week.
The federal agency confirmed a 66 percent rate of efficiency around the globe, according to Dr. Frita Frasier, founder and president of Midtown Atlanta Nephrology. The U.S. currently has a 72 percent rate of efficacy.
“The most important thing beyond it preventing that 66 or that 72 percent of moderate to severe disease,” Dr. Frasier said in an exclusive interview with BNC.
The Johnson & Johnson vaccine prevents 85 percent of people from being hospitalized, according to Dr. Frasier.
The FDA recently granted emergency approval of Covid-19 vaccines from Pfizer and Moderna, which has a rate between 94 to 95 percent of preventing serious illness.
While Johnson & Johnson’s rate of effectiveness is lower than both Pfizer and Moderna, Dr. Frasier’s said that it isn’t a cause for concern because testing for Johnson & Johnson’s vaccine began after variants from South Africa, the United Kingdom and Brazil sprang up over several months.
Dr. Frasier emphasizes the push to get vaccinated, saying that 72 percent, 66 percent, 84 percent is better the zero percent protection from this virus.”
The introduction of a third vaccination would benefit the US tremendously, according to an FDA analysis.
A total of 20 million doses will be ready by the end of March, which is 17 million fewer doses than the firm’s federal contact envisions, according to a report from The New York Times.
Johnson & Johnson told Congress that it will be able to meet its promised 100 million doses by the end of the summer, according to the Associated Press.
A decision from the FDA on Johnson & Johnson’s vaccine could come as early as Saturday.